

# ROYALTY PHARMA

## Royalty Pharma Acquires Additional Interest in TECFIDERA® for \$510 Million

NEW YORK, January 6, 2014 – Royalty Pharma announced today that it has acquired an additional interest in the earn-out payable to the former shareholders of Fumapharm AG for \$510 million in cash.

The Fumapharm earn-out primarily represents an indirect interest in sales of Biogen Idec's TECFIDERA® (dimethyl fumarate), an oral therapeutic for the treatment of relapsing-forms of multiple sclerosis. The earn-out also includes an indirect interest in sales of FUMADERM™, a therapeutic approved in Germany for the treatment of moderate to severe plaque psoriasis.

This acquisition follows Royalty Pharma's previous acquisition of an interest in the Fumapharm earn-out payments in May 2012 for \$761 million.

### About Royalty Pharma

Royalty Pharma is the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products, with royalty interests in 39 approved products (including Abbott's Humira®, Johnson & Johnson's Remicade®, Prezista®, and Imbruvica®, Merck's Januvia®/Janumet®, Gilead's Atripla®, Truvada®, Emtriva®, Complera® and Stribild®, Cubist's Cubicin® , Pfizer's Lyrica®, Amgen's Neupogen® and Neulasta®, and Genentech's Rituxan®) valued at over \$7 billion. Royalty Pharma has a seventeen year history of providing value to holders of royalty interests, including its \$400 million purchase of 80% of Memorial Sloan-Kettering Cancer Center's Neupogen®/Neulasta® royalty, its \$700 million acquisition of AstraZeneca's Humira royalty, its \$700 million purchase of a portion of Northwestern University's Lyrica royalty, its \$650 million purchase of New York University's Remicade royalty, its joint \$525 million acquisition with Gilead Sciences of Emory University's emtricitabine royalty interest, its \$609 million acquisition of Astellas Pharma's patent estate and associated royalty stream relating to the use of dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes, its \$761 million acquisition of a portion of the earn-out payable to the former shareholders of Fumapharm the value of which relates principally to Tecfidera®, and most recently its \$485 million acquisition of Quest Pharmaceutical's Imbruvica® royalty. More information on Royalty Pharma is available at [www.royaltypharma.com](http://www.royaltypharma.com).

Contact Information:

#### **Alexander v. Perfall**

VP, Investor Relations & Public Affairs

[aperfall@royaltypharma.com](mailto:aperfall@royaltypharma.com)

+ 1 (212) 883-2298